Wave Life Sciences director sells 1,127 shares to cover RSU taxes

Rhea-AI Filing Summary

What the filing shows: The Form 4 reports that Tan Aik Na, a director of Wave Life Sciences (WVE), sold 1,127 ordinary shares on August 5, 2025. The sale was made to cover taxes tied to the vesting of restricted share units and was executed pursuant to a 10b5-1 trading plan at a price of $8.75 per share. After the transaction the reporting person beneficially owned 14,988 shares.

Why the filing exists: This is a standard insider disclosure that records an insider sale made for tax withholding related to equity compensation and documents that the sale followed a prearranged plan.

Positive

• Sale executed under a 10b5-1 trading plan, indicating the transaction followed a prearranged compliance mechanism
• Disclosure lists post-transaction beneficial ownership (14,988 shares), providing transparency

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine tax-driven insider sale of 1,127 shares under a 10b5-1 plan; not a material market-moving event.

The Form 4 discloses a single insider sale executed to satisfy taxes from RSU vesting. The sale price is listed at $8.75 and was made under an established 10b5-1 trading plan, which typically reduces timing concerns about opportunistic trading. The remaining beneficial ownership reported is 14,988 shares. From a trading perspective, this type of transaction is generally neutral for investors absent larger or repeated disposals.

Corporate Governance Expert

TL;DR: Use of a 10b5-1 plan and prompt Form 4 disclosure reflect basic insider compliance and transparency.

The filing identifies the reporting person as a director and documents that the sale was to cover tax obligations from RSU vesting and was executed pursuant to a documented 10b5-1 plan. That combination—prearranged plan plus timely disclosure—aligns with good insider-trading governance practices. There is no indication in the filing of policy breaches or unusual timing beyond the RSU vesting event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tan Aik Na

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/05/2025		S		1,127(1)	D	$8.75	14,988	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On August 5, 2025, the reporting person sold 1,127 ordinary shares solely to cover taxes associated with the vesting of restricted share units on August 5, 2025.These sales were made pursuant to a 10b5-1 Trading Plan.

	/s/ Aik Na Tan	08/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Wave Life Sciences (WVE)?

Tan Aik Na, identified as a director of Wave Life Sciences, is the reporting person on the Form 4.

How many shares did the insider sell and why (WVE)?

The filing states the insider sold 1,127 ordinary shares to cover taxes associated with the vesting of restricted share units.

At what price were the shares sold in the WVE Form 4?

The reported sale price on the form is $8.75 per share.

Were the WVE sales executed under a trading plan?

Yes. The filing states the sales were made pursuant to a 10b5-1 trading plan.

How many shares did the reporting person own after the transaction (WVE)?

After the reported transaction the reporting person beneficially owned 14,988 shares.